# Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

> **NCT07148947** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 27 (estimated)

## Conditions studied

- Accelerated Phase Myeloproliferative Neoplasm
- Blast Phase Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Decitabine
- **DRUG:** Decitabine and Cedazuridine
- **DRUG:** Azacitidine
- **OTHER:** Survey Administration
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy

## Key facts

- **NCT ID:** NCT07148947
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07148947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07148947, "Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07148947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*